Compare DexCom, Inc. (DXCM) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Health Care Select Sector SPDR Fund — how do they compare? DexCom, Inc. trades at $84.15 (market cap $31.86B), while Health Care Select Sector SPDR Fund trades at $170.79 (market cap $43.48B). The key difference: Health Care Select Sector SPDR Fund is the larger of the two by market cap, and Health Care Select Sector SPDR Fund is more actively traded (11,121,431 versus 3,607,070). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Health Care Select Sector SPDR Fund for 100 Days on average.
| DXCM | XLV | |
|---|---|---|
Market Cap | $31.86B | $43.48B |
Volume | 3,607,070 | 11,121,431 |
Sector | Health | — |
52-Week High | $92.34 | $175.68 |
52-Week Low | $54.84 | $141.95 |
Typical Hold Time | 62 Days | 100 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
XLV trades at $170.86, up 1.21% with a bearish technical signal from moving averages while oscillators remain neutral. The healthcare ETF shows strong cost advantages with a 0.08% expense ratio compared to peers, holding 61 diversified healthcare stocks from the S&P 500. Recent news highlights XLV's defensive characteristics during potential Fed rate hikes and political volatility.
The ETF offers defensive exposure to healthcare with low costs, though technical indicators suggest near-term pressure. Key risks include sector-specific regulatory changes and election uncertainty, while the fund's diversification provides stability amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
